ICLR
ICON plc (NASDAQ: ICLR) announced that it will release its second quarter 2026 financial results on July...
Article Summary
HOLD- ICON plc (NASDAQ: ICLR) announced that it will release its second quarter 2026 financial results on July 29, 2026 after the market closes, followed by a conference call and webcast on July 30 at 8:00am ET to discuss performance.
- Icon is a world-leading clinical research organization delivering integrated consulting, clinical development, commercialization and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organizations worldwide.
- With headquarters in Dublin, Ireland, ICON employed approximately 40,350 employees in 97 locations in 55 countries as at March 31 of 2026, offering deep operational and medical expertise to accelerate innovation.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.8% | 25% | 20.0 ptsMinimal (0.8%) - Very weak |
| EPS Growth Next 5Y ? | 2.4% | 25% | 10.0 ptsVery Weak (2.4%) - Minimal expectations |
| Target Price Upside ? | 10.9% | 20% | 50.0 ptsMeets Minimum (10.9%) - Target: $183.60 vs Current: $165.51 |
| Gross Margin % ? | 20.7% | 15% | 40.0 ptsModerate (20.7%) - Adequate margins |
| Drawdown from 52-Wk High ? | -21.6% | 15% | 40.0 ptsMild Pullback (-21.6%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About ICLR
- ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
- The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
- It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.
- In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers.
- Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions.
- It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations.
- The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model.
- ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.